fashion -WSS

fashion

author：comprehensive 2025-09-03 11:50:59 - browse：21

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

WSS

Google says AlphaFold 3 can map a vast universe of biomolecules

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Group opposing PBM reform sets lobbying record

Shionogi licenses Pompe disease therapy from Maze Therapeutics

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

STAT Virtual Event: The State of Biosimilars: What to Watch

focus

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

A public scorecard can help hold safety

How one medical school became remarkably diverse

Sanders adds drug shortage policies to pandemic preparedness bill

Drug repurposing or repositioning? The language matters

What nurses really want: sufficient staffing for patient care

Heart attack and stroke risk calculators need revising

Study: Adult vaccinations pay for themselves in societal benefits

In age of alternative facts, a scholarly course on calling out crap

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Wikipedia

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

FDA approves RSV monoclonal antibody for infants, toddlers

Key House panel plots a new health care package

Medicare has a new plan to address drug shortages

Telehealth startups turn to complex chronic diseases

hotspot

focus

focus

leisure time